Macular Degeneration Health Center

Font Size
A
A
A

Anti-VEGF medicines for wet age-related macular degeneration (AMD)

Examples

Generic Name Brand Name
Bevacizumab Avastin
Pegaptanib Macugen
Ranibizumab Lucentis

These medicines are injected into the eye by your doctor. Before the injection, your doctor will numb the eye with eye drops.

How It Works

When wet age-related macular degeneration (AMD) develops, weak abnormal blood vessels grow under the retina and lead to vision loss. The growth of these vessels is triggered by a protein called vascular endothelial growth factor (VEGF). Anti-VEGF medicines block the effects of VEGF. Blocking this protein slows the growth of the abnormal blood vessels. This slows the vision loss linked to wet AMD.

Why It Is Used

Anti-VEGF medicines are used to slow the vision loss caused by wet AMD. These medicines slow the growth of abnormal blood vessels that leads to wet AMD.

How Well It Works

Anti-VEGF medicines can slow the vision loss that is linked to wet AMD. 1 They may also improve vision for people with wet AMD. 2 Because these medicines are relatively new, long-term effects are not yet known.

Side Effects

The common side effects of pegaptanib or ranibizumab injections include:

  • Changes in vision, or trouble seeing.
  • Inflammation of different parts of the eye.
  • Bleeding.
  • Eye discharge.
  • Eye pain or discomfort.
  • Increased pressure inside the eye.
  • Increased sensitivity to light.
  • Headache.
  • Painful urination.

Ranibizumab (Lucentis) may raise the risk of stroke in elderly people, especially if they have already had a stroke.

Many side effects may be caused by the actual injection procedure rather than the drug itself. For example, the injections have a risk of infection.

Long-term effects of these medicines are not yet known.

See Drug Reference for a full list of side effects. (Drug Reference is not available in all systems.)

What To Think About

You will likely get the injections on a regular basis, such as once a month.

Other types of anti-VEGF drugs are currently being studied, including some that may be injected into a vein (intravenously) rather than into the eye.

Anti-VEGF medicines may help stop vision loss in people who cannot benefit from other treatments such as laser photocoagulation or photodynamic therapy.

Complete the new medication information form (PDF)(What is a PDF document?) to help you understand this medication.

Citations

  1. Drugs for some common eye disorders (2007). Treatment Guidelines from The Medical Letter, 5(53): 4–5.

  2. Rosenfeld PJ, et al. (2006). Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine, 355(14): 1419–1431.

WebMD Medical Reference from Healthwise

Last Updated: August 13, 2007
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
webMD Video

Show or hide information about video: Macular Degeneration Camera   Macular Degeneration Camera

Macular degeneration is the leading cause of blindness in people over 60. But now an experimental surgery may help restore vision.

Watch Video: Macular Degeneration Camera (opens in a new window)

Show or hide information about video: Eye Nutrition

  Eye Nutrition

Show or hide information about video: Low Vision Aids   Low Vision Aids

Show or hide information about video: Macular Degeneration Study   Macular Degeneration Study

Show or hide information about video: Macular Degeneration Gene   Macular Degeneration Gene

Advertise on Fox News Channel, FOXNews.com and FOX News Radio Jobs at FOX News Channel. Internships at FOX News Channel (now accepting Fall interns).
Terms of use. Privacy Statement. For FOXNews.com comments write to foxnewsonline@foxnews.com; For FOX News Channel comments write to comments@foxnews.com
© Associated Press. All rights reserved.
SMARTMONEY ® © 2006 SmartMoney. SmartMoney is a joint publishing venture of Dow Jones & Company, Inc. and Hearst SM Partnership. All Rights Reserved.
All quotes delayed by 20 minutes. Delayed quotes provided by ComStock.
Historical prices and fundamental data provided by Hemscott, Inc.
Mutual fund data provided by Lipper. Mutual Fund NAVs are as of previous day's close.
Earnings estimates provided by Zacks Investment Research.
Upgrades and downgrades provided by Briefing.com.
This material may not be published, broadcast, rewritten, or redistributed. © 2006 FOX News Network, LLC. All rights reserved. All market data delayed 20 minutes.